Side-by-side comparison of AI visibility scores, market position, and capabilities
Mooresville NC home improvement retail (NYSE: LOW) ~$83.7B FY2024 revenue; 1,700 stores, Total Home Pro strategy, Kobalt private label, competing with Home Depot for professional contractor share.
Lowe's Companies, Inc. is a Mooresville, North Carolina-based home improvement retailer — publicly traded on the New York Stock Exchange (NYSE: LOW) as a Dow Jones Industrial Average and S&P 500 Consumer Discretionary component — operating approximately 1,700 home improvement stores across the United States and Canada offering tools, hardware, paint, flooring, appliances, plumbing, electrical, lumber, outdoor living, and installation services through approximately 300,000 employees. In fiscal year 2024 (ending January 2025), Lowe's reported revenues of approximately $83.7 billion, with comparable store sales declining modestly as the post-pandemic home improvement spending normalization — following the 2020-2022 surge in home renovation activity — continued to weigh on transaction counts, partially offset by average ticket growth from Pro customer project spending. CEO Marvin Ellison has executed the "Total Home Strategy" focused on Pro customer (professional contractors, electricians, plumbers, and tradespeople) penetration: Lowe's has historically underindexed versus Home Depot with the Pro customer (Home Depot Pro revenue 50%+ of total versus Lowe's Pro closer to 25-30% historically), and the Total Home strategy's Lowe's Pro investments (expanded Pro desk service, designated Pro parking, dedicated Pro account managers, buy-online-pickup-in-store for contractors, net-30 Pro credit accounts) aim to close this Pro gap. Lowe's online sales (15%+ of total revenue) grew through the Lowes.com marketplace expansion (adding third-party products beyond owned inventory), same-day delivery partnerships, and contractor-oriented digital tools (project estimating, product specification sheets, installation scheduling).
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.